...
首页> 外文期刊>The annals of pharmacotherapy >Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization.
【24h】

Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization.

机译:万古霉素对心脏手术患者的手术预防耐受性和耐万古霉素肠球菌定植的发生率。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In 2001, vancomycin replaced cefuroxime for antibiotic prophylaxis in patients undergoing cardiac surgery at our institution due to high rates of surgical site infections caused by methicillin-resistant Staphylococcus spp. However, few data supported the use of vancomycin for surgical prophylaxis. OBJECTIVE: To determine the tolerance of vancomycin for antibiotic prophylaxis and incidence of vancomycin-resistant Enterococcus (VRE) in cardiac surgery patients. METHODS: In 2 separate studies, we assessed the adverse effects in patients given perioperative vancomycin (study 1) and the incidence of VRE in patients given perioperative vancomycin (study 2). Study 1 was a prospective cohort study of patients undergoing coronary artery bypass graft (CABG) or valve replacement surgery given vancomycin (1 dose preoperatively/2 doses postoperatively) for antibiotic prophylaxis between October 2003 and December 2004. Patients were assessed for tolerance to the antibiotic regimen. In study 2, cardiac surgery patients receiving perioperative vancomycin were screened for VRE before therapy and at day 7 of hospitalization. VRE was detected using standard microbiologic procedures. RESULTS: In study 1, 1161 patients (CABG = 75%; valve = 19%; both = 6%) were evaluated. All patients but one (99.9%) were prescribed preoperative vancomycin. Therapy was changed for 34 (2.9%) patients, of which 20 changes were due to physician preference for another antibiotic. The only toxicity that required a change in the vancomycin regimen was red man's syndrome, which was experienced by 9 (0.8%) patients. Four patients did not receive a second postoperative dose due to prior renal insufficiency. Patients were most commonly switched to cefuroxime (n = 26), linezolid (n = 2), cefepime (n = 2), gatifloxacin, cefazolin, levofloxacin, or ceftriaxone (n = 1, each). In study 2, 100 patients were screened for the emergence of VRE colonization. No patient was VRE positive at baseline and 4 (4%) were positive at day 7. CONCLUSIONS: Surgical antibiotic prophylaxis with vancomycin was reasonably well tolerated in CABG and valve replacement surgery, with a 4% incidence of VRE colonization.
机译:背景:2001年,由于耐甲氧西林的葡萄球菌引起的手术部位感染率高,万古霉素在我院进行心脏手术的患者中替代了头孢呋辛,以预防抗生素的使用。但是,很少有数据支持使用万古霉素进行手术预防。目的:确定万古霉素对心脏外科手术患者抗生素预防的耐受性和耐万古霉素肠球菌(VRE)的发生率。方法:在两项独立的研究中,我们评估了围手术期万古霉素患者的不良反应(研究1)和围手术期万古霉素患者VRE的发生率(研究2)。研究1是一项前瞻性队列研究,研究对象是2003年10月至2004年12月接受冠状动脉旁路移植术(CABG)或瓣膜置换手术并接受万古霉素(术前1剂量/ 2术后2剂量)抗生素预防的患者。评估患者对抗生素的耐受性养生。在研究2中,接受围手术期万古霉素治疗的心脏手术患者在治疗前和住院第7天进行了VRE筛查。使用标准的微生物学程序检测VRE。结果:在研究1中,评估了1161例患者(CABG = 75%;瓣膜= 19%;两者均= 6%)。除一名患者外(99.9%),所有患者均接受术前万古霉素治疗。 34位患者(2.9%)改变了治疗方法,其中20位改变是由于医生偏爱另一种抗生素。需要改变万古霉素治疗方案的唯一毒性是红人综合症,有9名患者(0.8%)经历过这种综合症。由于先前的肾功能不全,四名患者没有接受第二次术后剂量。患者最常换用头孢呋辛(n = 26),利奈唑胺(n = 2),头孢吡肟(n = 2),加替沙星,头孢唑林,左氧氟沙星或头孢曲松(n = 1)。在研究2中,筛选了100例VRE菌落的出现。没有患者在基线时VRE阳性,第7天有4例(4%)阳性。结论:在CABG和瓣膜置换手术中,万古霉素的外科手术抗生素预防耐受性良好,VRE定植的发生率为4%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号